Navigation Links
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/25/2009

lion increase in expenses related to external research-related manufacturing and regulatory and quality assurance activities related to ANX-530 and ANX-514, a $1.3 million increase in external clinical trial expenses related to ANX-514 and a $0.2 million increase in personnel costs, offset by a $5.4 million decrease in external clinical trial expenses related to CoFactor and ANX-530 and a $0.3 million decrease in non-cash, stock-based compensation expenses. R&D expenses for 2008 included non-cash, stock-based compensation expenses amounting to $0.7 million, compared to $1.0 million for 2007.

SG&A expenses increased by $1.0 million, or 12%, to $9.7 million for 2008, from $8.7 million for 2007. The increase was substantially due to a $0.7 million increase in severance expenses, a $0.4 million increase for consulting expenses related to market research, a $0.3 million increase in personnel expenses and $0.1 million increase in professional services, offset by a $0.5 million decrease in non-cash, stock-based compensation expenses. SG&A expenses for 2008 included non-cash, stock-based compensation expenses amounting to $0.9 million, compared to $1.4 million for 2007.

Revenue of $500,000 in 2008 represents a portion of a settlement payment from Theragenex, LLC. In May 2008, we settled a dispute with Theragenex arising out of its alleged breach of a license agreement and, in accordance with such settlement, Theragenex paid us $0.6 million. We recognized $0.5 million as revenue, and the remainder, $0.1 million, as other income.

Interest income and other income amounted to $0.7 million for 2008, compared to $2.2 million in 2007. The decrease in interest income and other income was primarily attributable to lower interest income based on lower invested balances, offset by $0.1 million received as part of the Theragenex settlement, which was recorded as other income.

Balance Sheet Hi
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Further Cost-Cutting Measures
2. ADVENTRX Provides Update on Strategic Transaction Process
3. ADVENTRX Announces Further Cost-Cutting Measures
4. ADVENTRX Exploring Strategic Options
5. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
7. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. ADVENTRX Settles Dispute With Former Licensee
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. ADVENTRX Appoints Vice President of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... Sleepless nights ... an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers ... voice command technology makes it effortless to use, while the integration of the Bluetooth ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market ... including the molecular diagnostics industry. BCC Research reveals in its new report that the ... test costs, and a growing need for better diagnostics as part of a molecular ...
(Date:7/1/2015)... , ... July 01, 2015 , ... A newly launched ... ideas to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance ... two cash prizes of US$15,000 and a period of expert mentorship from a senior ...
(Date:6/30/2015)... 1, 2015 R-Japan Co.,Ltd. obtained the license of ... Regenerative Medicine from the Ministry of Health, Labour and Welfare ... The fact that R- Japan ... auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on May ... to provide stem cell manufacturing service to medical institutions. As ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... -- a North,American Advisory firm -- has been tapped ... conduct special analyses on China,s continuing,developmental efforts in specific ... on the top-tiered,areas of Beijing, Shanghai, and Tianjin, additional ... project. , (Photo: ...
... DSM,Biologics, a business unit of DSM Pharmaceutical Products, and ... Swiss Exchange:,CRX), today announced that Hungary-based Gedeon Richter Plc. signed ... biopharmaceuticals on the PER.C6(R) platform. , ... , About PER.C6(R) technology ...
... Tengion Inc., a clinical stage regenerative medicine company focused on ... M.D., President and Chief Executive Officer of Tengion, will present at ... 2008 at 9:50 a.m. EST at The Palace Hotel in New ... About Tengion , , ...
Cached Biology Technology:DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 2DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 4
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
(Date:6/24/2015)... Switzerland , June 24, 2015 ... partnership with emerging biometric password solution one face ... one face in, entering ... a ground-breaking and affordable multifactor-authentication biometric answer to ... recognition technology, provided in partnership with KeyLemon, one ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... DNA segments in the genome of bacteria. Every single ... we are able to identify bacterial strains as well ... how new pathogenic variants develop," says Manfred Hfle, researcher ... in the current issue of the scientific journal " ...
... from the British Antarctic Survey have collected individuals from a ... subjected them to increasing levels of water temperature to learn ... that they are likely to experience in the future. The ... really close to their upper temperature range, and that further ...
... Dallas, TX (June 29, 2009) -- A team of experts ... the South African bilateral amputee track athlete, have just published ... Some of their previously confidential findings were presented to ... in May of 2008. Other findings are now being ...
Cached Biology News:The tiny difference in the genes of bacteria 2Oscar Pistorius: Previously confidential study results released on amputee sprinter 2
...
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Rabbit polyclonal to SpUlp2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SNNERQSLSSGSND, corresponding to amino acids 622-635 of Schizosaccharomyces pombe SpUlp2...
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: